Entero Therapeutics Stock Price Falls Amid KDJ Death Cross and Bearish Marubozu Signal

The 15-minute chart for Entero Therapeutics indicates a bearish trend, as evidenced by the KDJ Death Cross and Bearish Marubozu pattern observed on October 21, 2025 at 3:30 PM. This suggests that the momentum of the stock price is shifting towards the downside, potentially leading to further decreases in the stock's value. Sellers currently have control of the market, and it is likely that this bearish momentum will continue.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has seen its stock price rise significantly, up by 61% to $2.13, following the release of preclinical data indicating that its drug, Mira-55, outperformed morphine in pain relief and inflammation in animal tests. The company, which operates as a clinical development stage biopharmaceutical company, specializes in developing products to address unmet medical needs in pain management, depression, PTSD, and cognitive function.

The stock's upward momentum has been noted by various analysts and traders. For instance, AxiomEx highlighted a notable upward momentum, with the stock price surging by 31.45% to close at $0.8610. Similarly, SPYDERMARKET pointed out that the company has extended its cash runway to about 16 months, indicating prudent financial management.

Despite the positive news, MIRA Pharmaceuticals' stock has not shown consistent growth. Over the past week, the stock has not changed significantly, while the month change indicates a −9.59% fall. However, over the last year, MIRA Pharmaceuticals has shown a 20.00% increase. Analysts have forecasted that the stock could reach a maximum of $3.00 and a minimum of $3.00, but these estimates should be taken with caution.

The stock's volatility is moderate, with a beta coefficient of 0.92. MIRA Pharmaceuticals is expected to release its next earnings report on December 3, 2025, with the last quarter's earnings showing a loss of $-0.09 per share. The company's revenue for the last quarter was $0.00, with no changes expected for the next quarter.

Given the current market conditions and technical analysis, investing in MIRA Pharmaceuticals' stock requires careful consideration. The stock shows a neutral signal for the next month, but further research is recommended before making any investment decisions.